The Company has stock-based compensation plans approved by its shareholders under which it grants stock options, restricted stock awards, restricted stock units and deferred stock units to officers, directors and key employees. Stock-based compensation expense was reported as follows in the condensed consolidated statements of operations:

	Three Months Ended				Six Months Ended
	March 31,				March 31,
(In thousands)	2021		2020		2021		2020
Product costs	$	32	$	15	$	69	$	48
Research and development		305		168		589		430
Selling, general and administrative		1,092		1,121		2,204		2,219
Total	$	1,429	$	1,304	$	2,862	$	2,697

As of March 31, 2021, approximately $10.1 million of total unrecognized compensation costs related to non-vested awards is expected to be recognized over a weighted average period of approximately 2.5 years.

During the six months ended March 31, 2021 and 2020, the Company awarded 234,000 and 261,000 options to officers, directors and key employees with a weighted average grant date fair value per option of $13.86 and $14.24, respectively.

During the six months ended March 31, 2021 and 2020, the Company awarded 65,000 and 60,000 restricted stock shares, respectively, to certain key employees and officers with a weighted average grant date fair value per share of $37.48 and $41.88, respectively.

During the six months ended March 31, 2021 and 2020, the Company awarded 12,000 and 17,000 restricted stock units, respectively, to directors and to key employees in foreign jurisdictions with a weighted average grant date fair value per unit of $45.13 and $40.73, respectively.

Our U.S. employees are eligible to participate in the amended 1999 Employee Stock Purchase Plan (“ESPP”) approved by our shareholders. Shares issued under the ESPP totaled 8,000 and 7,000 for the six months ended March 31, 2021 and 2020, respectively.